✦ LIBER ✦

P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications

✍ Scribed by R.A. Hauser; J.M. Gertner; M. Okamoto; R.F. Reed; J.I. Sage

Book ID: 117753663
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 134 KB
Volume: 15
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(09)70460-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idazoxan, an alpha-2 antagonist, and L-D

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc

Burden of L-Dopa-Induced Dyskinesia in P

Burden of L-Dopa-Induced Dyskinesia in Parkinson’s Disease Patients (PD-LID) in France – the Lidia Study Economic Analysis (Levodopa Induced Dyskinesia Impact Evaluation)

✍ Kryskowiak, P.; Viallet, F.; Brefel-Courbon, C.; Durif, F.; Ory-Magne, F.; Tison 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Sensitivity of EQ-5D to clinical change

Sensitivity of EQ-5D to clinical change in patients with parkinson’s disease L-dopa induced dyskinesia

✍ Petrillo, J.; Pendergraft, T.; Sacco, P.; Michalopoulos, S.; Oster, G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Zydis selegiline reduces off time in Par

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

✍ Cheryl H. Waters; Kapil D. Sethi; Robert A. Hauser; Eric Molho; John M. Bertoni 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 1 views

Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were exp